Vivo Bio Tech (BOM:511509) Cyclically Adjusted Revenue per Share: ₹47.17 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:511509 Vivo Bio Tech Ltd BOM:511509
63 GF Score
Price ₹21.44
GF Value ₹30.34
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Vivo Bio Tech Cyclically Adjusted Revenue per Share?

Vivo Bio Tech BOM:511509 +0.09% 63 Cyclically Adjusted Revenue per Share is ₹47.17 as of Jun. 2026. GuruFocus rates BOM:511509 with a GF Score™ of 63/100 and a GF Value™ of ₹30.34 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vivo Bio Tech's adjusted revenue per share for the three months ended in Jun. 2026 was ₹6.089. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹47.17 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vivo Bio Tech's average Cyclically Adjusted Revenue Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-02), Vivo Bio Tech's current stock price is ₹21.44. Vivo Bio Tech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹47.17. Vivo Bio Tech's Cyclically Adjusted PS Ratio of today is 0.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivo Bio Tech was 1.05. The lowest was 0.48. And the median was 0.79.


Vivo Bio Tech  (BOM:511509) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vivo Bio Tech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.44/47.17
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivo Bio Tech was 1.05. The lowest was 0.48. And the median was 0.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vivo Bio Tech Cyclically Adjusted Revenue per Share Related Terms


Vivo Bio Tech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vivo Bio Tech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivo Bio Tech Cyclically Adjusted Revenue per Share Chart

Vivo Bio Tech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 45.31 47.36 47.31

Vivo Bio Tech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.67 48.06 47.68 47.31 47.17

BOM:511509 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Vivo Bio Tech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivo Bio Tech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivo Bio Tech's Cyclically Adjusted PS Ratio falls into.


BOM:511509
63GF Score
Vivo Bio Tech Ltd BOM:511509
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivo Bio Tech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivo Bio Tech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.089/166.1454*166.1454
=6.089

Current CPI (Jun. 2026) = 166.1454.

Vivo Bio Tech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 8.778 105.961 13.764
201609 9.574 105.961 15.012
201612 9.099 105.196 14.371
201703 9.182 105.196 14.502
201706 11.654 107.109 18.078
201709 12.484 109.021 19.025
201712 13.016 109.404 19.767
201803 9.858 109.786 14.919
201809 14.147 115.142 20.414
201812 11.307 115.142 16.316
201903 11.145 118.202 15.665
201906 10.442 120.880 14.352
201909 10.619 123.175 14.324
201912 10.968 126.235 14.436
202003 11.198 124.705 14.919
202006 7.117 127.000 9.311
202009 11.360 130.118 14.505
202012 9.062 130.889 11.503
202103 10.694 131.771 13.484
202106 8.809 134.084 10.915
202109 6.972 135.847 8.527
202112 8.757 138.161 10.531
202203 11.030 138.822 13.201
202206 7.841 142.347 9.152
202209 8.413 144.661 9.662
202212 9.066 145.763 10.334
202303 9.608 146.865 10.869
202306 8.133 150.280 8.992
202309 6.235 151.492 6.838
202312 8.621 152.924 9.366
202403 7.889 153.035 8.565
202406 6.699 155.789 7.144
202409 8.071 157.882 8.493
202412 8.191 158.323 8.596
202503 7.980 157.552 8.415
202506 6.924 159.755 7.201
202509 6.792 162.289 6.953
202512 6.063 163.281 6.169
202603 6.932 164.272 7.011
202606 6.089 166.145 6.089

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹47.17 mean?
Vivo Bio Tech (BOM:511509) has a Cyclically Adjusted Revenue per Share of ₹47.17 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivo Bio Tech and its competitors.
Is Vivo Bio Tech's Cyclically Adjusted Revenue per Share too high?
Vivo Bio Tech's current Cyclically Adjusted Revenue per Share is ₹47.17. Overall, Vivo Bio Tech has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vivo Bio Tech's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Vivo Bio Tech's Cyclically Adjusted Revenue per Share of ₹47.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivo Bio Tech and its competitors. Vivo Bio Tech's current Cyclically Adjusted Revenue per Share is ₹47.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivo Bio Tech stock overvalued right now?
Based on GuruFocus' analysis, Vivo Bio Tech (BOM:511509) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹30.34, compared to a current price of ₹21.44 — trading 29.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹47.17. Vivo Bio Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vivo Bio Tech (BOM:511509), the current Cyclically Adjusted Revenue per Share is ₹47.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivo Bio Tech (BOM:511509) Overvalued in 2026?

Based on GuruFocus' analysis, Vivo Bio Tech stock appears to be undervalued. The current stock price of ₹21.44 is trading 29.3% below its estimated GF Value™ of ₹30.34. GuruFocus considers Vivo Bio Tech to be Modestly Undervalued.

Key valuation signals for BOM:511509:

  • Cyclically Adjusted Revenue per Share: ₹47.17
  • GF Value™: ₹30.34 vs. price of ₹21.44 (29.3% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the BOM:511509 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vivo Bio Tech Business Description

Address Number 8-2-672/ 5 & 6, Road Number 1, 3rd Floor, Ilyas Mohammed Khan Estate, Banjara hills, Hyderabad, TG, IND, 500034
Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.
63GF Score

Get the complete analysis for BOM:511509

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹21.44
Price
₹30.34
GF Value